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Introduction
Peptide amphiphiles (PAs) are composed of a combination of amino acids carrying hydrophobic/hydrophilic and positively/negatively charged residues. 1 PAs have been found to be promising tools in drug and gene delivery due to their biocompatibility and bioactivity. [2] [3] [4] These compounds are not toxic to cells at their experimental concentration and are able to cross the cell membrane because of their unique structural properties.
Hydrophobic unit of PAs can contain long chain fatty acids or amino acids with hydrophobic side chain residues. This unit generates a pocket that could be responsible for the entrapment of drugs and facilitates the internalization into the cell membrane. 5 At the same time, the presence of positively charged arginine facilitates the interaction between the peptide and the negatively charged phospholipids on the cell membrane. The application of positively charged linear cell-penetrating peptides (CPPs) as drug carriers for biologically active cargos has been reported previously. [6] [7] [8] [9] Polyarginines, TAT (trans-acting activator of transcription), and
Penetratin have been found to enhance the cellular uptake of a diverse range of drugs. [10] [11] [12] Thus, the appropriate combination of amino acids in the structure of peptide determines the efficiency and function of the delivery system.
Phosphopeptides are valuable reagent probes mimicking phosphoproteins for studying protein-protein and protein-ligand interactions 13, 14 and determination of substrate specificity of the Src homology 2 (SH2) domain, 15 phosphatases, 16, 17 and phosphotyrosine binding (PTB)
domains. 18, 19 The use of phosphopeptides has been challenging due to the fact that they have limited cellular uptake because of the presence of the negatively charged phosphate group.
Several chemical modifications have been used to enhance the intracellular delivery of phosphopetides through covalent conjugation to other transporter peptides. [20] [21] [22] These strategies suffer from several disadvantages including multistep synthesis of the fusion conjugates, low loading yields, and the requirement of cleavage through chemical or enzymatic reactions to release phosphopeptides. 23 Peptidomimetic prodrugs have been reported for intracellular delivery of aryl phosphoramidates 24 and difluoromethyl phosphonates 25 . Arrendale and co-workers developed a (difluoromethylene)phosphoserine prodrug to deliver negatively charged phosphoserine peptidomimetic intracellularly. FOXO3a is a transcription factor that is phosphorylated by Akt1
and binds to 14-3-3-adaptor protein. The released modified phosphopeptide was able to release
FOXO3a from 14-3-3 protein, leading to cell death in leukemia cells. 26, 27 Other phosphoserine and phosphothreonine masked phosphopeptides have been evaluated in studying kinase regulation. 28, 29 Considering the critical roles of the phosphopeptides in cellular signaling pathways, we have previously reported amphiphilic linear peptide analogues to improve the intracellular uptake of negatively charged phosphopeptides through noncovalent conjugation. 30 The linear positively charged peptides were designed based on the Src SH2 domain phosphotyrosine (pTyr) binding pocket.
We introduced a new class of homochiral cyclic peptides containing arginine (R) and 4 led to the formation of nanostructures through intermolecular interactions. To the best of our knowledge, this is the first report of using a cell-penetrating cyclic peptide for cellular delivery of impermeable phosphopeptides.
Experimental Section
General
All amino acids were purchased from Chem-Impex International, Inc. HBTU was purchased from Oakwood products, Inc. All other chemicals and reagents were purchased from Sigma- Similarly, other fluorescein-labeled peptides were synthesized according to this procedure. Consequently, a similar FACS protocol was performed as described above. (25 µM) for 1 h at 37 ºC. The stock solutions were prepared at high concentrations to generate maximum intermolecular interactions and then were diluted to desired concentrations for cellular studies. After 1 h incubation, the media containing the treatments were removed followed by washing with PBS three times. Then the coverslips were mounted on a microscope slide with mounting media with the cell-attached side facing down. Laser scanning confocal microscopy was carried out using Carl Zeiss LSM 510 system. The cells were imaged using FITC and phase contrast channels. mesh size 300, which was allowed to sit for 2 min. Excess solvent was carefully removed by capillary action (filter paper). Grids were allowed to dry at room temperature for overnight. All images were taken using JEOL transmission electron microscope (Tokyo, Japan) maintained at 80 kv. After drop casting of peptide solutions, grids were then stained with uranyl acetate (20 µL) for 2 min. Excess stain was removed, and the grids were allowed to dry overnight. A 180 s time interval between injections was applied in order to allow the system to reach thermal equilibrium after each addition. Corrections were made for the dilution heat of the phosphopeptide, which was determined in control experiments under similar conditions.
Ac-PE(pY)LGLD (shown here as PE(pY)LGLD
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Analysis of the integrated heat data was performed using the Origin 7 package provided with the ITC instrument. Experimental data was fitted using a nonlinear least-squares minimization algorithm to a theoretical titration curve. Different binding models were assumed, involving a single set of identical sites, two sets of independent sites, or sequential binding events. The equations were included in the commercial ITC Data analysis software package of Origin 7.0.
The chi-square parameter χ 2 was used to establish the best fit.
Circular Dichroism. CD spectra were recorded on a JASCO J-810 spectropolarimeter using 1 mm path length cuvettes. The scan speed was 100 nm/min, and spectra were averaged over 8 Geometry of monomers was completely optimized. All bond lengths, bond angles and dihedral angles were allowed to relax without any constraint. phosphopeptides by using appropriate resins and side chain protected amino acids.
RESULTS AND DISCUSSION
Chemistry
Scheme 1. Solid-Phase Synthesis of Ac-PE(pY)LGLD and F′-PE(pY)
LGLD.
Cellular Uptake Studies
The cellular uptake of synthesized fluorescence-labeled phosphopeptides (10 µM) was The cellular uptake and internalization of many CPPs along with the conjugated cargo occurs predominantly via an endocytic pathway that involves macropinocytosis, caveolae pathway, clathrin-mediated endocytosis, or lipid-raft dependent endocytosis. The nature of the cell lines and the presence and type of the cargo could affect the specific mechanism employed by the CPP. 36 We have previously shown that the cellular uptake of [WR] 4 was independent of endocytosis. 31a Thus, the mechanism of the cellular uptake of the complex mixture of [WR] 4 and F′-PEpYLGLD was evaluated in the presence of different inhibitors to determine whether the cargo changes the uptake mechanism.
To perform the ATP depletion, sodium azide was incubated with cells for 30 min prior to the incubation with the complex followed by 1 h incubation. Significant intracellular uptake of The interaction between PEpYLGLD and [WR] 4 was visualized by using TEM. The stable mixture of [WR] 4 and PEpYLGLD was prepared at a high concentration to achieve the maximum interaction. An optimized balance between the hydrophobic and electrostatic interactions generated by the drug and the carrier led to the formation of nanosized particles.
[WR] 4 generated self-assembled nanostructures after one day incubation at room temperature. 4 and PEpYLGLD was further confirmed by ITC studies. To the best of our knowledge, this is the first report of using cyclic peptides for noncovalent cellular delivery of cell impermeable phosphopeptides. These data provide insights about using cell penetrating cyclic peptides as PAs for delivery of negatively charged cell impermeable phophopeptides.
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